Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme

Abstract Introduction Biosimilars have provided additional treatment options for patients with immune-mediated inflammatory diseases. This study evaluated the real-world use of adalimumab biosimilar ABP 501 in European patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic a...

Description complète

Détails bibliographiques

Auteurs principaux:	Ran Jin, James M. Haughton, Emily J. Goddard, Delphine Courmier, Waldemar Radziszewski, Rachael H. Meadows, James Piercy, Stanley Cohen
Format:	Artigo
Langue:	Inglês
Publié:	Adis, Springer Healthcare 2025-03-01
Collection:	Rheumatology and Therapy
Sujets:	Adalimumab Ankylosing spondylitis Biosimilar Patient-reported outcomes Psoriasis Psoriatic arthritis
Accès en ligne:	https://doi.org/10.1007/s40744-025-00755-9
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!